Microbiota, NASH, HCC and the potential role of probiotics

Carcinogenesis

Volumn 38, Issue 3, 2017, Pages 231-240

  Brandi, Giovanni ^a,b   De Lorenzo, Stefania ^a   Candela, Marco ^b   Pantaleo, Maria Abbondanza ^a,b   Bellentani, Stefano ^c   Tovoli, Francesco ^b   Saccoccio, Gioconda ^d   Biasco, Guido ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Centre Point Clinic   (United Kingdom)

^d Regional Agency for Health Care Bologna   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

DYSBIOSIS; GENOMICS; HUMAN; INTESTINE FLORA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER DISEASE; METABOLISM; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; LIVER TUMOR; MICROBIOLOGY; PATHOLOGY; RISK FACTOR;

CARCINOMA, HEPATOCELLULAR; GASTROINTESTINAL MICROBIOME; HUMANS; LIVER NEOPLASMS; NON-ALCOHOLIC FATTY LIVER DISEASE; PROBIOTICS; RISK FACTORS;

EID: 85028569756     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgx007     Document Type: Review

References (151)

1. International Agency for Research for Cancer (IARC) (2012) GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://www.iacr.com
2. El-Serag, H.M. et al. (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-2576
3. Parkin, D.M. (2001) Global cancer statistics in the year 2000. Lancet Oncol., 2, 533-543
4. Bosch, F.X. et al. (2004). Primary liver cancer: worldwide incidence and trends. Gastroenterology, 127, S5-S16
5. El-Serag, H.B. et al. (1999) Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med., 340, 745-750
6. Siddique, A. et al. (2011) Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin. Liver Dis., 15, 281-96, vii
7. Ong, J.P. et al (2007) Epidemiology and natural history of NAFLD and NASH. Clin. Liver Dis., 211, 1-6
8. Bellentani, S. et al. (2000) Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med., 132, 112-117
9. Starley, B.Q. et al. (2010) Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology, 51, 1820-1832
10. Shimada, M. et al. (2002) Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J. Hepatol., 37, 154-160
11. Bhala, N. et al. (2011) The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology, 54, 1208-1216
12. Asha, M.S. et al. (2010). The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology, 51, 1972-1978
13. White, D.L. et al. (2012) Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin. Gastroenterol. Hepatol., 10, 1342-1359.e2
14. Tilg, H. et al. (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology, 52, 1836-1846
15. Abenavoli, L. et al. (2013) Probiotics in non-alcoholic fatty liver disease: which and when. Ann. Hepatol., 12, 357-363
16. Musso, G. et al. (2010) Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. Curr. Opin. Lipidol., 21, 76-83
17. Eckburg, P.B. et al. (2005) Diversity of the human intestinal microbial flora. Science, 308, 1635-1638
18. O'Hara, A.M. et al. (2006) The gut flora as a forgotten organ. EMBO Rep., 7, 688-693
19. Qin, J. et al. (2010). A human gut microbial gene catalogue established by metagenomic sequencing. Nature, 464, 59-65
20. Huycke, M.M. et al. (2004) Commensal bacteria, redox stress, and colorectal cancer: mechanisms and models. Exp. Biol. Med. (Maywood), 229, 586-597
21. Iida, N. et al. (2013) Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science, 342, 967-970
22. Viaud, S. et al. (2013) The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science, 342, 971-976
23. Khachatryan, Z.A. et al. (2008) Predominant role of host genetics in controlling the composition of gut microbiota. PLoS One, 3, e3064
24. Atumugam, M. et al. (2011). Enterotypes of the human gut microbiome. Nature, 473, 174-180
25. Stearns, J.C. et al. (2011) Bacterial biogeography of the human digestive tract. Sci. Rep., 1, 170
26. Zoetendal, E.G. et al. (1998). Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl. Environ. Microbiol., 64, 3854-3859
27. Sokol, H. et al. (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. USA, 105, 16731-16736
28. Quévrain, E. et al. (2016) Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease. Gut, 65, 415-425
29. Turnbaugh, P.J. et al. (2009) The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci. Transl. Med., 1, 1-10
30. Turnbaugh, P.J. et al. (2008) Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microb., 3, 213-223
31. Claesson, M.J. et al. (2012) Gut microbiota composition correlates with diet and health in the elderly. Nature, 488, 178-184. 32 Human Microbiome Project Consortium (2012). Structure, function and diversity of the healthy human microbiome. Nature, 486, 207-214
32. David, L.A. et al. (2014) Diet rapidly and reproducibly alters the human gut microbiome. Nature, 505, 559-563
33. Petersen, C. et al. (2014) Defining dysbiosis and its influence on host immunity and disease. Cell. Microbiol., 16, 1024-1033
34. Carding, S. et al. (2015) Dysbiosis of the gut microbiota in disease. Microb. Ecol. Health Dis., 26, 26191
35. Richard, M.L. et al. (2015) Gut fungal microbiota: the Yin and Yang of inflammatory bowel disease. Inflamm. Bowel Dis., 21, 656-665
36. Turnbaugh, P.J. et al. (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature, 444, 1027-1031
37. Cani, P.D. et al. (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes, 56, 1761-1772
38. Ley RE, et al. (2006). Microbial ecology: human gut microbes associated with obesity. Nature, 21, 1022-1023
39. Zhu, L. et al. (2013) Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology, 57, 601-609
40. Mouzaki, M. et al. (2013) Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology, 58, 120-127
41. Qin, N. et al. (2014) Alterations of the human gut microbiome in liver cirrhosis. Nature, 513, 59-64
42. Clemente, J.C. et al. (2012) The impact of the gut microbiota on human health: an integrative view. Cell, 148, 1258-1270
43. Tremaroli, V. et al. (2012) Functional interactions between the gut microbiota and host metabolism. Nature, 489, 242-249
44. Flint, H.J. et al. (2008) Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis. Nat. Rev. Microbiol., 6, 121-131
45. Koropatkin, N.M. et al. (2012) How glycan metabolism shapes the human gut microbiota. Nat. Rev. Microbiol., 10, 323-335
46. Fischbach, M.A. et al. (2011) Eating for two: how metabolism establishes interspecies interactions in the gut. Cell Host Microb., 10, 336-347
47. Sonnenburg, E.D. et al. (2010) Specificity of polysaccharide use in intestinal bacteroides species determines diet-induced microbiota alterations. Cell, 141, 1241-1252
48. Rakoff-Nahoum, S. et al. (2014) An ecological network of polysaccharide utilization among human intestinal symbionts. Curr. Biol., 24, 40-49
49. Miller, T.L. et al. (1982) Enumeration of Methanobrevibacter smithii in human feces. Arch. Microbiol., 131, 14-18
50. Schwab, C. et al. (2011) Diet and environment shape fecal bacterial microbiota composition and enteric pathogen load of grizzly bears. PLoS One, 6, e27905
51. Smith, E.A. et al. (1997) Dissimilatory amino Acid metabolism in human colonic bacteria. Anaerobe, 3, 327-337
52. Moco, S. et al. (2014) Systems biology approaches for inflammatory bowel disease: emphasis on gut microbial metabolism. Inflamm. Bowel Dis., 20, 2104-2114
53. Nichilson, J.K. et al. (2012) Host-gut microbiota metabolic interactions. Science, 336, 1262-1267
54. Besten, D.G. et al. (2013) The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid. Res., 54, 2325-2340
55. Neish, A.S. (2009) Microbes in gastrointestinal health and disease. Gastroenterology, 136, 65-80
56. De Vadder, F. et al. (2014) Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell, 156, 84-96
57. Segain, J.P. et al. (2000) Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut, 47, 397-403
58. Trompette, A. et al. (2014) Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med., 20, 159-166
59. Holmes, E. et al. (2012) Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell Metab., 16, 559-564
60. Devkota, S. et al. (2012) Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/-mice. Nature, 487, 104-108
61. Cox, L.M. et al. (2014) Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell, 158, 705-721
62. Dethlefsen, L. et al. (2011) Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl. Acad. Sci. USA, 108 (suppl. 1), 4554-4561
63. Reijnders, D. et al. (2016) Effects of gut microbiota manipulation by antibiotics on host metabolism in obese humans: a randomized double-blind placebo-controlled trial. Cell Metab., 24, 63-74
64. Brandi, G. et al. (2013) Intestinal microbiota around colorectal cancer genesis. In The research and biology of cancer II, iConcept Press
65. Gagnière, J. et al. (2016) Gut microbiota imbalance and colorectal cancer. World J. Gastroenterol., 22, 501-518
66. Abu-Shanab, A. et al. (2010) The role of the gut microbiota in nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol., 7, 691-701
67. Schaffert, C.S. et al. (2009) Alcohol metabolites and lipopolysaccharide: roles in the development and/or progression of alcoholic liver disease. World J. Gastroenterol., 15, 1209-1218
68. Cani, P.D. et al. (2009) The role of the gut microbiota in energy metabolism and metabolic disease. Curr. Pharm. Design, 13, 1546-1558
69. Loguercio, C. et al. (2002) Gut-liver axis: a new point of attack to treat chronic liver damage? Am. J. Gastroenterol., 97, 2144-2146
70. Tilg, H. et al. (2009) Obesity and the microbiota. Gastroenterology, 136, 1476-1483
71. Le Chatelier, E. et al. (2013) Richness of human gut microbiome correlates with metabolic markers. Nature, 500, 541-546
72. Bäckhed, F. et al. (2004) The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA, 101, 15718-15723
73. Bäckhed, F. et al. (2007) Mechanisms underlying the resistance to dietinduced obesity in germ-free mice. Proc. Natl. Acad. Sci. USA, 104, 979-984
74. Cani, P.D. et al. (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes, 57, 1470-1481
75. Zhou, X. et al. (2014). A model of metabolic syndrome and related diseases with intestinal endotoxemia in rats fed a high sucrose diet. PLoS One, 12, e115148
76. Kirpich, I.A. et al. (2012) The type of dietary fat modulates intestinal tight junction integrity, gut permeability, and hepatic toll-like receptor expression in a mouse model of alcoholic liver disease. Alcohol. Clin. Exp. Res., 36, 835-846
77. Machado, M.V. et al. (2012) Gut microbiota and nonalcoholic fatty liver disease. Ann. Hepatol., 11, 440-449
78. Artis, D. (2008) Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat. Rev. Immunol., 8, 411-420
79. Ding S, et al. (2010). High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity resistance in mouse. PLoS One, 5, e12191
80. Ye, D. et al. (2006) Molecular mechanism of tumor necrosis factor-alpha modulation of intestinal epithelial tight junction barrier. Am. J. Physiol. Gastrointest. Liver Physiol., 290, G496-G504
81. Wiest R, et al. (2003) Bacterial translocation in the gut. Best Pract. Res. Clin. Gastroenterol., 17, 397-425
82. Szabo, G. et al. (2010) Gut-liver axis and sensing microbes. Dig. Dis., 28, 737-744
83. Compare, D. et al. (2012) Gut-liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis., 22, 471-476
84. Cesaro, C. et al. (2011) Gut microbiota and probiotics in chronic liver diseases. Dig. Liver Dis., 43, 431-438
85. Wigg, A.J. et al. (2001) The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut, 48, 206-211
86. Miele, L. et al. (2009) Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology, 49, 1877-1887
87. Norman, K. et al. (2008) Gastrointestinal tract in liver disease: which organ is sick? Curr. Opin. Clin. Nutr. Metab. Care, 11, 613-619
88. Alisi A, et al. (2012). Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. Front Cell Infect Microbial., 2, 132
89. Lade, A. et al. (2014) Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Curr. Opin. Oncol., 26, 100-107
90. Miyake, Y. et al. (2013) Role of gut microbiota in liver diseases. Hepatol. Res., 43, 139-146
91. Nagata, K. et al. (2007) Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J. Toxicol. Sci., 32, 453-468
92. Nagy, L.E. (2003) Recent insights into the role of the innate immune system in the development of alcoholic liver disease. Exp. Biol. Med. (Maywood), 228, 882-890
93. Thuy, S. et al. (2008). Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator 1 concentrations and with fructose intake. J. Nutr., 138: 1452-1455
94. Rivera, C.A. et al. (2007) Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol., 47, 571-579
95. Miura, K. et al. (2010) Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology, 139, 323-34.e7
96. Spruss, A. et al. (2009) Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology, 50, 1094-1104
97. Li, Z. et al. (2005) Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology, 42, 880-885
98. Strowing T, et al. (2012). Inflammasome in health and disease. Nature, 481, 133-144
99. Szabo, G. et al. (2012) Inflammasomes in liver diseases. J. Hepatol., 57, 642-654
100. Martinon, F. et al. (2009) The inflammasomes: guardians of the body. Annu. Rev. Immunol., 27, 229-265
101. Bauernfeind, F. et al. (2011) Inflammasomes: current understanding and open questions. Cell. Mol. Life Sci., 68, 765-783
102. Henao-Merjia J, et al. (2012). Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature, 482, 179-185
103. Csak, T. et al. (2011) Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology, 54, 133-144
104. Vandanmagsar B, et al. (2011). The NALP3/NLRP3 inflammasome instigates obesity-induced autoinflammation and insulin resistance. Nat. Med., 17: 179-188
105. Netea, M.G. et al. (2006) Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat. Med., 12, 650-656
106. Li, Y. et al. (2013) Bile acid receptors in non-alcoholic fatty liver disease. Biochem. Pharmacol., 86, 1517-1524
107. Swann, J.R. et al. (2011) Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci USA, 108, 4523-4530
108. Sayin, S.I. et al. (2013) Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab., 17, 225-235
109. Musso, G. et al. (2010) Emerging molecular targets for the treatment of nonalcoholic fatty liver disease. Annu. Rev. Med., 61, 375-392
110. Kong, B. et al. (2009) Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J. Pharmacol. Exp. Ther., 328, 116-122
111. McMahan, R.H. et al. (2013) Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J. Biol. Chem., 288, 11761-11770
112. Jiang, C. et al. (2015) Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J. Clin. Invest., 125, 386-402
113. Yu, L.X. et al. (2010) Endotoxin accumulation prevents carcinogeninduced apoptosis and promotes liver tumorigenesis in rodents. Hepatology, 52, 1322-1333
114. Dapito, D.H. et al. (2012) Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell, 21, 504-516
115. Yoshimoto, S. et al. (2013) Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature, 499, 97-101
116. Ohtani, N. et al. (2013) Roles and mechanisms of cellular senescence in regulation of tissue homeostasis. Cancer Sci., 104, 525-530
117. Coppé, J.P. et al. (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol., 6, 2853-2868
118. Kuilman, T. et al. (2009) Senescence-messaging secretome: SMS-ing cellular stress. Nat. Rev. Cancer, 9, 81-94
119. Roskams, T. et al. (1998) Hepatic OV-6 expression in human liver disease and rat experiments: evidence for hepatic progenitor cells in man. J. Hepatol., 29, 455-463
120. Haque, S. et al. (1996) Identification of bipotential progenitor cells in human liver regeneration. Lab. Invest., 75, 699-705
121. Fujita, M. et al. (2000) Sequential observation of liver cell regeneration after massive hepatic necrosis in auxiliary partial orthotopic liver transplantation. Mod. Pathol., 13, 152-157
122. Ray, M.B. et al. (1993). Bile duct changes in alcoholic liver disease. Liver, 13: 36-45
123. Roskams, T.A. et al. (2003) Progenitor cells in diseased human liver. Semin. Liver Dis., 23, 385-396
124. Carpino, G. et al. (2013) Role of hepatic progenitor cells in nonalcoholic fatty liver disease development: cellular cross-talks and molecular networks. Int. J. Mol. Sci., 14, 20112-20130
125. Roskams, T. et al. (2003) Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am. J. Pathol., 163, 1301-1311
126. Libbrecht, L. et al. (2000) Deep intralobular extension of human hepatic 'progenitor cells' correlates with parenchymal inflammation in chronic viral hepatitis: can 'progenitor cells' migrate? J. Pathol., 192, 373-378
127. Lowes, K.N. et al. (1999) Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am. J. Pathol., 154, 537-541
128. Richardson, M.M. et al. (2007) Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology, 133, 80-90
129. Libbrecht, L. et al. (2000) The immunohistochemical phenotype of dysplastic foci in human liver: correlation with putative progenitor cells. J. Hepatol., 33, 76-84
130. Libbrecht, L. et al. (2001) Hepatic progenitor cells in hepatocellular adenomas. Am. J. Surg. Pathol., 25, 1388-1396
131. Uenishi, T. et al. (2003) Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci., 94, 851-857
132. Durnez, A. et al. (2006) The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology, 49, 138-151
133. Ozturk, Z.A. et al. (2014) Insulin sensitizers for the treatment of nonalcoholic fatty liver disease. World J. Hepatol., 6, 199-206
134. Nseir, W. et al. (2014) Role of diet and lifestyle changes in nonalcoholic fatty liver disease. World J. Gastroenterol., 20, 9338-9344
135. Walsh, C.J. et al. (2014) Beneficial modulation of the gut microbiota. FEBS Lett., 588, 4120-4130
136. Khan, M.T. et al. (2014) Antioxidants keep the potentially probiotic but highly oxygen-sensitive human gut bacterium Faecalibacterium prausnitzii alive at ambient air. PLoS One, 9, e96097
137. Dao, M.C. et al (2016). Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut, 65, 426-36
138. Chassard, C. et al. (2014) Probiotics tailored to the infant: a window of opportunity. Curr. Opin. Biotechnol., 26, 141-147
139. de Vos, W.M. (2013) Fame and future of faecal transplantations-developing next-generation therapies with synthetic microbiomes. Microb. Biotechnol., 6, 316-325
140. Petrof, E.O. et al. (2013) Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome, 1, 3
141. Angelberger, S. et al. (2013) Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am. J. Gastroenterol., 108, 1620-1630
142. Song, Y. et al. (2013) Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLoS One, 8, e81330
143. Kibe, R. et al. (2014) Upregulation of colonic luminal polyamines produced by intestinal microbiota delays senescence in mice. Sci. Rep., 4, 4548
144. Wagnerberger, S. et al. (2013) Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model. J. Nutr. Biochem., 24, 531-538
145. Raso, G.M. et al. (2014) Effects of a Lactobacillus paracasei B21060 based synbiotic on steatosis, insulin signaling and toll-like receptor expression in rats fed a high-fat diet. J. Nutr. Biochem., 25, 81-90
146. Endo, H. et al. (2013) Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis. PLoS One, 8, e63388
147. Xu, R.Y. et al. (2012) Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. J. Clin. Biochem. Nutr., 50, 72-77
148. Loguerio, C. et al. (2005). Beneficial effects of a probiotic VSL≠3 on parameters of liver dysfunction in chronic liver diseases. J. Clin. Gastroenterol., 39, 540-543
149. Malaguarnera, M. et al. (2012) Bifidobacterium longum with fructooligosaccharides in patients with non alcoholic steatohepatitis. Dig. Dis. Sci., 57, 545-553
150. Wong, V.W. et al. (2013) Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann. Hepatol., 12, 256-262
151. Eslamparast, T. et al. (2014) Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am. J. Clin. Nutr., 99, 535-542